[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582238":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":66,"collaborators":26,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NSAID","EXPERIMENTAL","Participants will receive an intravenous (IV) ketorolac 0.5mg\u002Fkg\u002Fdose, 15mg maximum, for no more than 8 doses in keeping with the investigators' routine clinical practice. Participants will then receive the oral (PO) ibuprofen suspension 10mg\u002Fkg\u002Fdose, 400mg maximum. The total duration of intervention (IV + PO) will not exceed 5 days.",[13],"Drug: NSAIDs",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","The IV formulation will be Normal Saline. The PO formulation will be compounded to have a similar look, volume, consistency and taste to the experimental medication. Participants will receive the IV formulation for no more than 8 doses. Participants will then receive the PO formulation. The total duration of intervention (IV + PO) will not exceed 5 days.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","NSAIDs","IV formulation: ketorolac 0.5mg\u002Fkg\u002Fdose, 15mg maximum, no more than 8 doses total PO formulation: ibuprofen suspension 10mg\u002Fkg\u002Fdose, 400mg maximum Total duration (IV + PO) will not exceed 5 days.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"IV or PO medication, compounded to have similar look, consistency and taste to the corresponding medications",[15],[31],{"name":32,"affiliation":33,"role":34},"Kyle Rove, MD","Children's Hospital Colorado","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","7209758206","kyle.rove@childrenscolorado.org",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Jennifer Pyrzanowski, MSPH","413-329-5321","Jennifer.pyrzanowski@cuanschutz.edu",[45],{"facility":33,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Aurora","Colorado","80045","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-104.83192,39.72943,{"lat":56,"lon":55},[59,62,65],{"name":41,"role":37,"phone":60,"phoneExt":26,"email":61},"4133295321","jennifer.pyrzanowski@cuanschutz.edu",{"name":63,"role":37,"phone":26,"phoneExt":26,"email":64},"Gemma Beltran, MPH","gemma.beltran@cuanschutz.edu",{"name":32,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":67,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100582238","phase-4-safety-of-short-course-of-nsaids-in-pediatric-patients-with-ckd-100582238",false,"NCT06860711","Safety of Short-course of NSAIDs in Pediatric Patients With CKD","Safety of Short-term NSAID Use in the Postoperative Setting in Pediatric Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients over 18 months of age\n* diagnosis of CKD stages 2-3a, confirmed by CKiD U25 eGFR calculator based on cystatin C laboratory testing within 6 months of surgery\n* Patient is scheduled to undergo a urologic surgery requiring admission or overnight stay in the hospital\n\nExclusion Criteria:\n\n* Diagnosis of CKD stage 1 or 4-5\n* Past medical history of renal transplant\n* Past medical history of nasal polyp\n* Procedure for oncologic indications or on chemotherapy\n* Pregnant patient\n* True allergy to NSAIDs","ALL","18 Months","25 Years",{"count":79,"type":80},164,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk. This is currently in the process of developing multi institution collaboration within a Pediatric Urology population, intended to inform future work in a larger patient population.",[86,87],"Chronic Kidney Disease","Pediatric Urology",[23,89,90,91,92],"CKD","Pediatrics","Urology","post-surgical","2026-06-04",{"date":95,"type":96},"2026-06-08","ACTUAL",{"date":98,"type":96},"2025-07-22",{"date":100,"type":80},"2028-12",{"name":5,"class":6},1]